BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 30, 2014
View Archived Issues
Novel monoclonal antibodies presented by the University of Texas System
Read More
Cancer Research UK launches trial of antibody for treatment of lymphoma
Read More
Novel PDE4 inhibitor appears to have limited emetic potential
Read More
Morphosys provides overview of development pipeline
Read More
Gilead Sciences details outlook for 2014
Read More
Genfit reports new preclinical data on anticancer effects of GFT-505
Read More
Viralytics begins phase I trial of Cavatak in solid tumors
Read More
Nimbus Discovery patents novel IRAK-4 inhibitors
Read More
Pfizer recaps recent pipeline highlights
Read More
Chiesi Farmaceutici discloses new neutrophil elastase inhibitors
Read More
FDA clears path for smoking cessation trial of INV-102
Read More
Ares Trading, a subsidiary of Merck Serono, patents new IRAK-4 inhibitors
Read More
Researchers at ViiV Healthcare disclose novel agents for HIV infection
Read More
Quest PharmaTech to conduct phase II trial of oregovomab combined with Hiltonol
Read More
Roche prepares new agents for RSV infection
Read More
PCI Biotech gives update on ENHANCE study
Read More
VA-694 inhibits COX-2, releases nitric oxide and demonstrates beneficial cardiovascular effects
Read More
Omeros reports data from phase IIa OMS-824 trial
Read More
OPS-202 receives EMA orphan drug designation for management of neuroendocrine tumors
Read More
KaloBios' phase II study of KB-003 in severe asthma misses primary endpoint
Read More
Seikagaku files for Japanese approval of SI-6603 for treatment of lumbar disc herniation
Read More
Biogen and UCB sign exclusive agreements to commercialize therapies for MS and hemophilia in Asia
Read More
Mesoblast reports positive outcomes from phase II trial on back pain
Read More
Cell Therapeutics reports initiation of phase II trial of pacritinib in patients with AML
Read More
Michael J. Fox Foundation provides overview of development conducted under its Partnering Program
Read More